Moderna’s Covid-19 vaccine would not have scaled without Ginkgo Bioworks. Reshma Shetty, co-founder and COO of Ginkgo – slated to go public via SPAC acquisition at a reported $15 billion valuation – explains how biotech innovation can build a better future now. The key, Shetty says, is propelling progress but not at the expense of principles. Engineering genes is a high-stakes pursuit, so Ginkgo is trying to pair the ambition of Silicon Valley with a “higher level of care.”